scholarly journals Knockdown of serine/threonine-protein kinase 24 promotes tumorigenesis and myeloid-derived suppressor cell expansion in an orthotopic immunocompetent gastric cancer animal model

2020 ◽  
Vol 11 (1) ◽  
pp. 213-228
Author(s):  
Hui-Ping Hsu ◽  
Chih-Yang Wang ◽  
Pei-Yin Hsieh ◽  
Jung-Hua Fang ◽  
Yi-Ling Chen
2019 ◽  
Vol Volume 11 ◽  
pp. 4023-4040 ◽  
Author(s):  
WeiHong Ren ◽  
XuRan Zhang ◽  
WenBo Li ◽  
Qian Feng ◽  
HuiJie Feng ◽  
...  

2018 ◽  
Vol 40 (1) ◽  
pp. 91-97 ◽  
Author(s):  
Liu Yang ◽  
Bing Wang ◽  
Jian Qin ◽  
HengHua Zhou ◽  
Adhip P. N. Majumdar ◽  
...  

2019 ◽  
Vol 26 (11) ◽  
pp. 2314-2328 ◽  
Author(s):  
Chuan-xia Zhang ◽  
Shu-biao Ye ◽  
Jian-jiao Ni ◽  
Ting-ting Cai ◽  
Yi-na Liu ◽  
...  

2020 ◽  
Vol 8 (1) ◽  
pp. e000485 ◽  
Author(s):  
Kien Thiam Tan ◽  
Chun-Nan Yeh ◽  
Yu-Chan Chang ◽  
Jen-Hao Cheng ◽  
Wen-Liang Fang ◽  
...  

BackgroundImmunological checkpoint blockade is effective in treating various malignancies. Identifying predictive biomarkers to assist patient selection for immunotherapy has become a priority in both clinical and research settings.MethodsMutations in patients who responded to immunotherapy were identified through next-generation sequencing. Relationships among protein kinase, DNA-activated, catalytic polypeptide (PRKDC) mutations, mutation load and microsatellite instability (MSI) were analyzed using datasets from The Cancer Genome Atlas. These relationships were validated by conducting an in vitro study and by using tissue samples from 34 patients with gastric cancer. The CT26 animal model was used to evaluate the role of PRKDC as a predictive biomarker and the efficacy of the DNA-PK inhibitor.ResultsFrom the published literature, we found that among patients whose tumors harboredPRKDCmutations, 75%, 53.8%, and 50% of those with lung cancer, melanoma, and renal cell carcinoma, respectively, responded to immunotherapy. Most of these mutations were truncating and located in functional domains or in a destabilizing PRKDC protein structure. Additional analysis showed that aPRKDCmutation was significantly associated with a high mutation load in cervical cancer, colon adenocarcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma, gastric adenocarcinoma and endometrial cancer. Patients with gastric cancer or colon cancer harboringPRKDCmutations were also highly associated with MSI-high status. Finally, we found that knockout PRKDC or DNA-PK inhibitor (PRKDCencodes the catalytic subunit of DNA-dependent protein kinase) enhanced the efficacy of the anti-programmed cell death protein one pathway monoclonal antibody in the CT26 animal model.ConclusionsPRKDC is not only a predictive biomarker but also a drug target for immune checkpoint inhibitors.


2015 ◽  
Vol 63 (2) ◽  
pp. 579-585 ◽  
Author(s):  
Eva Sahakian ◽  
John J. Powers ◽  
Jie Chen ◽  
Susan L. Deng ◽  
Fengdong Cheng ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document